shinelogo

A Janesville based nuclear technology company has submitted a drug master file with the F-D-A for a radio-pharmaceutical at the forefront of precision cancer treatment.

General Manager for Therapeutics Chris Vessell says Shine Technologies intends to produce Lu-177 with more common materials so that they don’t have to go through countries like Russia to get the rare earth elements needed.

Vessell says that the DMF submission for Lu-177 lets clients reference Shine’s documents and know they’re getting an FDA approved ingredient.

In targeted cancer therapy, Lu-177 is paired with a cancer seeking molecule to directly target and attack cancer cells.

 

Loading...